0000899243-21-007232.txt : 20210218
0000899243-21-007232.hdr.sgml : 20210218
20210218204422
ACCESSION NUMBER: 0000899243-21-007232
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Pienta Kenneth
CENTRAL INDEX KEY: 0001571862
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38327
FILM NUMBER: 21651676
MAIL ADDRESS:
STREET 1: C/O CURIS, INC.
STREET 2: 4 MAGUIRE ROAD
CITY: LEXINGTON
STATE: MA
ZIP: 02421
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cue Biopharma, Inc.
CENTRAL INDEX KEY: 0001645460
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 473324577
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 617-949-2680
MAIL ADDRESS:
STREET 1: 21 ERIE STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Imagen Biopharma, Inc.
DATE OF NAME CHANGE: 20150617
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-16
0
0001645460
Cue Biopharma, Inc.
CUE
0001571862
Pienta Kenneth
C/O CUE BIOPHARMA, INC.
21 ERIE STREET
CAMBRIDGE
MA
02139
0
1
0
0
Chief Medical Officer
Common Stock
2021-02-16
4
M
0
16000
2.86
A
18000
D
Common Stock
2021-02-16
4
S
0
16000
15.1514
D
2000
D
Common Stock
2021-02-17
4
M
0
1280
2.86
A
3280
D
Common Stock
2021-02-17
4
M
0
2994
5.00
A
6274
D
Common Stock
2021-02-17
4
S
0
4274
15.055
D
2000
D
Stock Option (right to buy)
2.86
2021-02-16
4
M
0
16000
0.00
D
2023-11-16
Common Stock
16000
1280
D
Stock Option (right to buy)
2.86
2021-02-17
4
M
0
1280
0.00
D
2023-11-16
Common Stock
1280
0
D
Stock Option (right to buy)
5.00
2021-02-17
4
M
0
2994
0.00
D
2024-04-17
Common Stock
2994
147006
D
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.06 to $15.60, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.20, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The option, representing a right to purchase a total of 20,000 shares, became exercisable in full on November 16, 2017.
The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.
/s/ Kenneth Pienta by Colin Sandercock, attorney-in-fact
2021-02-18